- PN: B111359
45x Ab-conjugated beads (S4P7 - human APRIL Ab-bead). PN: B111359A. One vial containing 100 µL of anti-human APRIL conjugated to AimPlex Bead S4P7.
25x Biotin-detection Ab (human APRIL Biotin-dAb). PN: B111359B. One vial containing 100 µL of biotinylated anti-human APRIL.
Lyophilized Standard -Human APRIL. PN: B111359S. One vial containing lyophilized recombinant human APRIL.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human APRIL/TNFSF13/sCD256. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Sample volume: 15 µL/test
A proliferation-inducing ligand (APRIL), also known as tumor necrosis factor ligand superfamily member 13 (TNFSF13), is a protein of the TNF superfamily recognized by the cell surface receptor TACI. APRIL is also designated CD256. This protein is a ligand for TNFRSF17/BCMA and its receptor are found to be important for B cell development. In vivo experiments suggest an important role for APRIL in the long-term survival of plasma cells in the bone marrow. Mice deficient in APRIL showed a reduced ability to support plasma cell survival In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Diseases associated with TNFSF13 include brain glioblastoma multiforme and glioblastoma multiforme.
1. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (Sep 1998). "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth". The Journal of Experimental Medicine 188 (6): 1185–90. doi:10.1084/jem.188.6.1185. PMC 2212534. PMID 9743536.
2. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA (Mar 2008). "APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells". Blood 111 (5): 2755–64. doi:10.1182/blood-2007-09-110858. PMID 18180376.
3. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP (Nov 2000). "Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS". The Journal of Biological Chemistry 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.
4. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS (Oct 2002). "BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases". Journal of Immunology 169 (8): 4314–21. doi:10.4049/jimmunol.169.8.4314. PMID 12370363.